On January 16, 2024, LingyiMed (Hangzhou) Co., Ltd, a biotechnology company, successfully obtained an implied permission from the National Medical Products Administration (NMPA) for the Investigational New Drug (IND) clinical trials of its new therapeutic biological product, LY-M001 Injection. This development marks a significant step in the company’s research efforts, with the acceptance number registered as CXSL2300730.
LY-M001 Injection is notable for being the first AAV gene therapy drug developed in China aimed at treating Type I or Type III Gaucher Disease. Utilizing recombinant adeno-associated virus (rAAV) as a vector, the drug facilitates the expression of glucocerebrosidase, essential for patients, through a single intravenous administration. LingyiMed has innovated in this field by developing a modified glucocerebrosidase gene therapy vector, which they hold full intellectual property rights to. This vector is designed for long-term stable expression in the body, targeting the degradation of harmful glycolipid metabolites, thereby potentially offering a long-term treatment option for Gaucher Disease.
The initiation of an IIT clinical research project, spearheaded by Dr. Dean Huang He of the First Affiliated Hospital of Zhejiang University School of Medicine, aligns with these developments. The project has reportedly started with the administration to the first patient and preliminary data suggests positive results in terms of efficacy and safety, with no adverse events recorded.
Dr. Lin Qing, the founder and CEO of LingyiMed, expressed confidence in the progress, emphasizing the milestone as a testament to the team’s capability in transitioning from drug discovery to clinical development. Additionally, LingyiMed endeavors in international markets are evidenced by the acceptance of their IND application for LY-M001 Injection by the U.S. Food and Drug Administration (FDA) in December 2023.
LingyiMed has made strides in AAV gene therapy drugs, thanks in part to the comprehensive CMC services provided by a notable CRO & CTDMO, PackGene. This collaboration has been pivotal for the project’s advancement. The CRO & CTDMO involved is set to continue its substantial role in the gene therapy sector, offering integrated CMC solutions to foster drug innovation and the advancement of high-quality projects.
PackGene, established in 2014, is known for its commitment to making gene therapy more accessible and affordable. The company has positioned itself as a leader in AAV vector CRO services, serving clients from over 20 countries, including top multinational pharmaceutical companies and research institutions. With its focus on innovative technology and advanced vector production, PackGene seeks to establish a strong international presence in the gene therapy CRO and CTDMO sectors.
Check out our AAV CDMO service to expedite your gene therapy research
https://mp.weixin.qq.com/s/H9srA6B-rI5z4s4MEQZEWA
PackGene Biotech is a world-leading CRO and CDMO, excelling in AAV vectors, mRNA, plasmid DNA, and lentiviral vector solutions. Our comprehensive offerings span from vector design and construction to AAV, lentivirus, and mRNA services. With a sharp focus on early-stage drug discovery, preclinical development, and cell and gene therapy trials, we deliver cost-effective, dependable, and scalable production solutions. Leveraging our groundbreaking π-alpha 293 AAV high-yield platform, we amplify AAV production by up to 10-fold, yielding up to 1e+17vg per batch to meet diverse commercial and clinical project needs. Moreover, our tailored mRNA and LNP products and services cater to every stage of drug and vaccine development, from research to GMP production, providing a seamless, end-to-end solution.
Related News
Exploring Tau Protein’s Role in Glaucoma: New Insights and Therapeutic Potential
Glaucoma, a chronic neurodegenerative disorder, leads to irreversible vision loss by damaging retinal ganglion cells (RGCs) and the optic nerve, often associated with increased intraocular pressure (IOP). Despite the benefits of IOP-lowering treatments, the underlying...
FDA-mandated CAR-T monitoring period could be halved, say researchers
In patients with diffuse large B-cell non-Hodgkin lymphoma (DLBCL), the two hallmark post-chimeric antigen receptor (CAR)-T therapy toxicities are extremely rare after two weeks, supporting a shorter, more flexible toxicity monitoring period, according to a study...
Ancestral CRISPR-Cas13 Ribonucleases Discovered: Implications for Genome Editing
In a pioneering study published in *Science*, a team of researchers led by Peter H. Yoon and Jennifer A. Doudna from the University of California, Berkeley, has made a remarkable discovery in the realm of CRISPR technology. The team has identified an ancestral clade...
KBI Biopharma Expands Manufacturing Contract with Global Pharmaceutical Company
KBI Biopharma Inc., a JSR Life Sciences company and global cGMP contract development and manufacturing organization (CDMO), has extended and expanded its manufacturing contract with a leading global pharmaceutical company. Originally initiated in 2020, the renewed...
Related Services
Plasmids GMP Services
AAV GMP Services
